Type of information: Financing round
Company: VBL Therapeutics/Vascular Biogenics (Israel)
Funding type: financing round
- Vascular Biogenics, operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on oncology. Its lead product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. Efficacy signals have been observed in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
- VBL Therapeutics intends to use the net proceeds from the offering for the advancement of clinical programs, product development, and for working capital and other general corporate purposes.
- • On November 17, 2017, Vascular Biogenics, operating as VBL Therapeutics, announced the pricing of its previously announced underwritten public offering of 2,500,000 ordinary shares for gross proceeds of $18,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. The offering is subject to customary closing conditions and is expected to close on or about November 21, 2017.
- • On November 16, 2017, VBL Therapeutics announced that it is offering to sell 2,500,000 ordinary shares in an underwritten public offering. Piper Jaffray & Co. is acting as the sole manager in this offering. Piper Jaffray & Co. proposes to offer the ordinary shares from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the Nasdaq Global Market, or to dealers in negotiated transactions or in combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices.
Therapeutic area: Cancer - Oncology